RXST · Rxsight, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $30.89M | - | $30.34M | $33.64M | $37.90M | - | $35.31M | $34.89M | $29.51M | - |
| Cost of Revenue | $7.39M | - | $6.11M | $8.45M | $9.57M | - | $10.09M | $10.64M | $8.83M | - |
| Gross Profit | $23.50M | - | $24.23M | $25.19M | $28.33M | - | $25.22M | $24.25M | $20.68M | - |
| R&D | $9.47M | - | $9.06M | $10.22M | $10.37M | - | $8.84M | $8.29M | $8.03M | - |
| SG&A | $31.86M | - | $27.34M | $28.98M | $28.64M | - | $25.61M | $24.29M | $23.32M | - |
| Total Operating Expenses | $41.33M | - | $36.41M | $39.19M | $39.00M | - | $34.45M | $32.58M | $31.36M | - |
| D&A | $834.0K | - | - | - | $776.0K | - | - | - | $1.11M | - |
| Operating Income | ($17.83M) | - | ($12.18M) | ($14.00M) | ($10.67M) | - | ($9.23M) | ($8.33M) | ($10.67M) | - |
| Interest Expense | $3.0K | - | $4.0K | $5.0K | $6.0K | - | $5.0K | $6.0K | $6.0K | - |
| Income Tax | $6.0K | - | $10.0K | $32.0K | $18.0K | - | $13.0K | $16.0K | $9.0K | - |
| Net Income | ($15.88M) | - | ($9.82M) | ($11.79M) | ($8.19M) | - | ($6.34M) | ($6.08M) | ($9.10M) | - |
| EPS - Basic | ($0.38) | - | ($0.24) | ($0.29) | ($0.20) | - | ($0.16) | ($0.16) | ($0.25) | - |
| EPS - Diluted | ($0.38) | - | ($0.24) | ($0.29) | ($0.20) | - | ($0.16) | ($0.16) | ($0.25) | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $17.57M | $19.95M | $29.63M | $40.35M | $28.00M | $16.71M | $16.72M | $24.45M | $32.65M | $9.69M |
| Accounts Receivable | $22.44M | $23.38M | $24.15M | $28.06M | $30.96M | $30.05M | $25.37M | $25.72M | $21.55M | $20.28M |
| Inventory | $34.87M | $31.56M | $28.95M | $25.06M | $23.57M | $22.01M | $21.67M | $19.44M | $18.70M | $17.42M |
| Accounts Payable | $7.12M | $5.30M | $3.38M | $3.35M | $7.11M | $4.54M | $4.58M | $5.09M | $5.06M | $3.86M |
| Current Assets | $279.23M | $287.46M | $283.88M | $283.87M | $288.41M | $293.82M | $286.77M | $281.22M | $168.56M | $168.41M |
| Total Assets | $303.99M | $311.81M | $308.53M | $309.01M | $313.04M | $318.56M | $310.47M | $305.50M | $183.16M | $182.55M |
| Current Liabilities | $27.38M | $26.25M | $22.29M | $20.38M | $22.74M | $25.88M | $22.64M | $19.62M | $18.33M | $20.90M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | $0 |
| Total Liabilities | $36.70M | $36.13M | $32.56M | $31.00M | $33.73M | $37.33M | $33.21M | $30.29M | $19.24M | $22.19M |
| Stockholders' Equity | $267.30M | $275.68M | $275.97M | $278.01M | $279.32M | $281.24M | $277.26M | $275.21M | $163.93M | $160.36M |
| Retained Earnings | ($676.92M) | ($661.04M) | ($651.89M) | ($642.07M) | ($630.28M) | ($622.10M) | ($616.16M) | ($609.82M) | ($603.74M) | ($594.64M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($10.89M) | - | - | - | ($8.83M) | - | - | - | ($9.31M) | - |
| Investing Cash Flow | $8.85M | - | - | - | $20.86M | - | - | - | $24.27M | - |
| Financing Cash Flow | ($336.0K) | - | - | - | ($735.0K) | - | - | - | $7.99M | - |
| CapEx | $759.0K | - | - | - | $575.0K | - | - | - | $1.97M | - |
| Free Cash Flow | ($11.65M) | - | - | - | ($9.41M) | - | - | - | ($11.28M) | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | 76.1% | - | 79.9% | 74.9% | 74.8% | - | 71.4% | 69.5% | 70.1% | - |
| Operating margin | -57.7% | - | -40.1% | -41.6% | -28.2% | - | -26.1% | -23.9% | -36.2% | - |
| EBITDA margin | -55.0% | - | - | - | -26.1% | - | - | - | -32.4% | - |
| Net margin | -51.4% | - | -32.4% | -35.0% | -21.6% | - | -17.9% | -17.4% | -30.8% | - |
| Free cash flow margin | -37.7% | - | - | - | -24.8% | - | - | - | -38.2% | - |
| FCF / Net income | 0.73 | - | - | - | 1.15 | - | - | - | 1.24 | - |
| R&D / Revenue | 30.7% | - | 29.9% | 30.4% | 27.4% | - | 25.0% | 23.8% | 27.2% | - |
| SG&A / Revenue | 103.1% | - | 90.1% | 86.1% | 75.6% | - | 72.5% | 69.6% | 79.0% | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -5.2% | - | -3.2% | -3.8% | -2.6% | - | -2.0% | -2.0% | -5.0% | - |
| Return on equity | -5.9% | - | -3.6% | -4.2% | -2.9% | - | -2.3% | -2.2% | -5.6% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 10.20 | 10.95 | 12.74 | 13.93 | 12.68 | 11.36 | 12.67 | 14.33 | 9.20 | 8.06 |
| Quick ratio | 8.93 | 9.75 | 11.44 | 12.70 | 11.65 | 10.50 | 11.71 | 13.34 | 8.18 | 7.22 |
| Cash ratio | 0.64 | 0.76 | 1.33 | 1.98 | 1.23 | 0.65 | 0.74 | 1.25 | 1.78 | 0.46 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | 0.00 |
| Debt / Assets | - | - | - | - | - | - | - | - | - | 0.00 |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | -5943.0x | - | -3044.5x | -2800.6x | -1779.0x | - | -1845.2x | -1388.8x | -1778.3x | - |
| Equity multiplier | 1.14 | 1.13 | 1.12 | 1.11 | 1.12 | 1.13 | 1.12 | 1.11 | 1.12 | 1.14 |
| Liabilities / Assets | 0.12 | 0.12 | 0.11 | 0.10 | 0.11 | 0.12 | 0.11 | 0.10 | 0.11 | 0.12 |
| Efficiency | ||||||||||
| Asset turnover | 0.10 | - | 0.10 | 0.11 | 0.12 | - | 0.11 | 0.11 | 0.16 | - |
| Inventory turnover | 0.21 | - | 0.21 | 0.34 | 0.41 | - | 0.47 | 0.55 | 0.47 | - |
| Days sales outstanding | 265d | - | 291d | 304d | 298d | - | 262d | 269d | 267d | - |
| Days inventory outstanding | 1721d | - | 1729d | 1083d | 899d | - | 784d | 667d | 773d | - |
| Days payable outstanding | 352d | - | 202d | 145d | 271d | - | 166d | 175d | 209d | - |
| Cash conversion cycle | 1635d | - | 1817d | 1243d | 926d | - | 880d | 761d | 831d | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | 1.0x | - | 1.3x | 1.9x | 3.7x | - | 7.1x | 8.4x | 11.6x | - |
| P / S | 8.2x | - | 12.1x | 15.7x | 27.0x | - | 55.7x | 66.3x | 64.4x | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | -18.5% | - | -14.1% | -3.6% | 28.4% | - | 59.1% | 67.6% | 68.7% | - |
| Revenue CAGR (3y) | 20.9% | - | 34.0% | 43.6% | 61.8% | - | 82.7% | 92.4% | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | -17.1% | - | -3.9% | 3.9% | 37.0% | - | 83.7% | 101.8% | 99.5% | - |
| Operating income growth (YoY) | -67.0% | - | -32.0% | -68.0% | -0.0% | - | 26.3% | 38.8% | 18.5% | - |
| Net income growth (YoY) | -93.9% | - | -54.9% | -93.9% | 10.0% | - | 48.9% | 56.0% | 31.1% | - |
| EPS growth (YoY) | -90.0% | - | -50.0% | -81.2% | 20.0% | - | 54.3% | 60.0% | 40.5% | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | -23.8% | - | - | - | 16.6% | - | - | - | 39.1% | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -4.3% | -2.0% | -0.5% | 1.0% | 70.4% | 75.4% | 71.7% | 75.1% | 13.0% | 78.4% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Product / service
$134.48M totalRxlal$108.06M · 80.4%
LDD$20.67M · 15.4%
Service Warranty Service Contracts And Accessories$5.75M · 4.3%
Peer comparison
Same SIC group: Ophthalmic Goods
Comparing RxSight against the 5 most active filers in the same SIC group.